TapewireFind a company

person · Reporting owner

Apeiron Investment Group Ltd.

Disclosed activity across 6 companies

Tapewire entity
10106
SEC CIK
0001845711

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Atai Beckley N.V.ATAI · Entity 7253610% ownerSeptember 30, 2025October 02, 2025
Enhanced Group Inc.ENHA · Entity 6262Director · 10% ownerSeptember 17, 2026September 22, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Atai Beckley N.V.

Report date September 30, 2025 · Filed October 02, 2025

Jointly reported with Angermayer Christian

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeIndirectBy Apeiron Investment Group Ltd.53,412,414 Reported balance After 2025-09-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2025-09-30 · Conversion · Acquired 2,367,200 · Balance 53,412,414

F1: The conversion price for the Convertible Notes is EUR 17.00 per note.

Convertible NotesSEC Table II · derivative / convertible security · Expires 2025-09-30IndirectBy Apeiron Investment Group Ltd.0 Reported balance After 2025-09-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2025-09-30 · Conversion · Disposed 147,950 · Balance 0

F1: The conversion price for the Convertible Notes is EUR 17.00 per note.

F2: The Convertible Notes were acquired in exchange for convertible notes issued by ATAI Life Sciences AG with substantially similar terms and economics.

Common SharesSEC Table I · non-derivativeIndirectBy Apeiron Presight Capital Fund II, L.P.1,799,302 Reported balance Holding disclosure · report date 2025-09-30 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 1,799,302

Filing footnotes · ownership attribution and instrument terms

F1: The conversion price for the Convertible Notes is EUR 17.00 per note.

F2: The Convertible Notes were acquired in exchange for convertible notes issued by ATAI Life Sciences AG with substantially similar terms and economics.

Enhanced Group Inc.

Report date September 17, 2026 · Filed September 22, 2026

Jointly reported with Enhanced Holdings LP, Angermayer Christian

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeIndirectSee Footnote43,343,818 Reported balance After 2026-09-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2026-09-17 · Purchase · Acquired 6,080,047 · Balance 43,343,818

F1: The securities reported herein are held of record by Apeiron Investment Group Ltd. ("Apeiron"), as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported herein are held of record by Apeiron Investment Group Ltd. ("Apeiron"), as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Alto Neuroscience, Inc.

Report date February 06, 2024 · Filed March 06, 2024

Jointly reported with Apeiron Presight Capital Fund II, L.P., Angermayer Christian

Section 16 reporting ended · disclosed 2024-03-06. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect251,881 Reported balance After 2024-02-06 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2024-02-06 · Conversion · Acquired 251,881 · Balance 251,881

F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.

F2: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.

Common StockSEC Table I · non-derivativeIndirectBy Apeiron Presight Capital Fund II, L.P.(674,658 Reported balance After 2024-02-06 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2024-02-06 · Conversion · Acquired 674,658 · Balance 674,658

F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.

F3: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.

Warrants to Purchase Series A Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2024-02-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2024-02-06 · Conversion · Disposed 444,561 · Balance 0

F4: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis.

F2: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.

Series A Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2024-02-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2024-02-06 · Conversion · Disposed 406,072 · Balance 0

F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.

F2: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.

Series A Preferred StockSEC Table II · derivative / convertible securityIndirectBy Apeiron Presight Capital Fund II, L.P.0 Reported balance After 2024-02-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2024-02-06 · Conversion · Disposed 1,063,918 · Balance 0

F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.

F3: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectBy Apeiron Presight Capital Fund II, L.P.0 Reported balance After 2024-02-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2024-02-06 · Conversion · Disposed 416,665 · Balance 0

F5: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis.

F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.

F3: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.

F2: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.

F3: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.

F4: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis.

F5: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis.

AtaiBeckley Inc.

Report date September 11, 2026 · Filed September 11, 2026

Jointly reported with Angermayer Christian

Section 16 reporting ended · disclosed 2026-09-11. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2026-09-11 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2026-09-11 · Disposition to issuer · Disposed 559,232 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.

F2: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding.

Common StockSEC Table I · non-derivativeIndirectBy ApeironInvestmentGroup Ltd.0 Reported balance After 2026-09-11 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2026-09-11 · Disposition to issuer · Disposed 53,398,214 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.

F2: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding.

F3: The Reporting Person's prior Form 4 inadvertently reported an incorrect beneficial ownership total, which has been corrected in this Form 4.

Common StockSEC Table I · non-derivativeIndirectBy ApeironPresightCapital FundII, L.P.0 Reported balance After 2026-09-11 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2026-09-11 · Disposition to issuer · Disposed 1,799,302 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.

F2: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding.

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.68 · Expires 2030-08-20Direct0 Reported balance After 2026-09-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-09-11 · Disposition to issuer · Disposed 624,000 · Balance 0

F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.84 · Expires 2032-05-25Direct0 Reported balance After 2026-09-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2026-09-11 · Disposition to issuer · Disposed 64,000 · Balance 0

F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2033-05-23Direct0 Reported balance After 2026-09-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-09-11 · Disposition to issuer · Disposed 17,930 · Balance 0

F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2034-01-05Direct0 Reported balance After 2026-09-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2026-09-11 · Disposition to issuer · Disposed 1,247,932 · Balance 0

F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.49 · Expires 2035-06-02Direct0 Reported balance After 2026-09-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2026-09-11 · Disposition to issuer · Disposed 131,698 · Balance 0

F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2035-06-26Direct0 Reported balance After 2026-09-11 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2026-09-11 · Disposition to issuer · Disposed 103,000 · Balance 0

F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2036-06-04Direct0 Reported balance After 2026-09-11 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2026-09-11 · Disposition to issuer · Disposed 121,968 · Balance 0

F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.

F2: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding.

F3: The Reporting Person's prior Form 4 inadvertently reported an incorrect beneficial ownership total, which has been corrected in this Form 4.

F4: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

BIONOMICS LTD/ADR

Report date July 01, 2024 · Filed October 07, 2024

Jointly reported with Apeiron Presight Capital Fund II, L.P., Angermayer Christian

Section 16 reporting ended · disclosed 2024-10-07. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeIndirectBy Apeiron Presight Capital Fund II, L.P.125,996,580 Reported balance After 2024-10-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2024-10-02 · Sale · Disposed 90,806 · Balance 125,996,580

F1: Includes Ordinary Shares represented by American Depositary Shares.

F2: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.

Ordinary SharesSEC Table I · non-derivativeIndirectBy Apeiron Presight Capital Fund II, L.P.93,469,320 Reported balance After 2024-10-03 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2024-10-03 · Sale · Disposed 180,707 · Balance 93,469,320

F1: Includes Ordinary Shares represented by American Depositary Shares.

F2: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.

Ordinary SharesSEC Table I · non-derivativeIndirectBy Apeiron Presight Capital Fund II, L.P.93,369,060 Reported balance After 2024-10-04 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2024-10-04 · Sale · Disposed 557 · Balance 93,369,060

F1: Includes Ordinary Shares represented by American Depositary Shares.

F2: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.

Ordinary SharesSEC Table I · non-derivativeIndirectBy Apeiron Investment Group Ltd.183,121,441 Reported balance Holding disclosure · report date 2024-07-01 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 183,121,441

F1: Includes Ordinary Shares represented by American Depositary Shares.

F3: The reportable securities are held by Apeiron. Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.

Filing footnotes · ownership attribution and instrument terms

F1: Includes Ordinary Shares represented by American Depositary Shares.

F2: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.

F3: The reportable securities are held by Apeiron. Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.

Faeth Therapeutics, Inc.

Report date June 01, 2023 · Filed June 02, 2023

Jointly reported with Angermayer Christian, Presight Sensei Co-Invest Fund, L.P., Presight Co-Invest Management, L.L.C.

Section 16 reporting ended · disclosed 2023-06-02. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Apeiron Investment Group Ltd.0 Reported balance After 2023-06-01 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2023-06-01 · Sale · Disposed 2,485,923 · Balance 0

F1: This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2: Securities owned directly by Apeiron. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Apeiron.

Common StockSEC Table I · non-derivativeIndirectBy Presight Sensei Co-Invest Fund, L.P.0 Reported balance After 2023-06-01 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2023-06-01 · Sale · Disposed 955,738 · Balance 0

F1: This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3: Securities owned directly by Presight Co-Invest. As the general partner of Presight Co-Invest, Presight Co-Invest Management may be deemed to beneficially own the securities owned directly by Presight Co-Invest. As the sole member of Presight Co-Invest Management, Apeiron may be deemed to beneficially own the securities owned directly by Presight Co-Invest. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Presight Co-Invest.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2: Securities owned directly by Apeiron. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Apeiron.

F3: Securities owned directly by Presight Co-Invest. As the general partner of Presight Co-Invest, Presight Co-Invest Management may be deemed to beneficially own the securities owned directly by Presight Co-Invest. As the sole member of Presight Co-Invest Management, Apeiron may be deemed to beneficially own the securities owned directly by Presight Co-Invest. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Presight Co-Invest.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 17, 2026 Filed Sep 22, 2026 01:30 UTC Enhanced Group Inc. ENHA · Entity 6262 PurchaseClass A Common Stock 6,080,047 $1.15 $6,992,054.05
Disclosure

SEC source: 0001193125-26-397056 · ownership.xml · nonDerivative · entry 1

Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner

Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 43,343,818

F1 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Ltd. ("Apeiron"), as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
September 11, 2026 Filed Sep 11, 2026 21:44 UTC AtaiBeckley Inc. ATAI · Entity 4289 Disposition to issuerStock Option · Derivative 121,968 Not disclosed Strike: $4.50 Not disclosed
Disclosure

SEC source: 0001140361-26-036377 · form4.xml · derivative · entry 10

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 121,968 shares

Expires 2036-06-04

F4 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

Read SEC document
September 11, 2026 Filed Sep 11, 2026 21:44 UTC AtaiBeckley Inc. ATAI · Entity 4289 Disposition to issuerStock Option · Derivative 103,000 Not disclosed Strike: $2.25 Not disclosed
Disclosure

SEC source: 0001140361-26-036377 · form4.xml · derivative · entry 9

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 103,000 shares

Expires 2035-06-26

F4 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

Read SEC document
September 11, 2026 Filed Sep 11, 2026 21:44 UTC AtaiBeckley Inc. ATAI · Entity 4289 Disposition to issuerStock Option · Derivative 131,698 Not disclosed Strike: $2.49 Not disclosed
Disclosure

SEC source: 0001140361-26-036377 · form4.xml · derivative · entry 8

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 131,698 shares

Expires 2035-06-02

F4 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

Read SEC document
September 11, 2026 Filed Sep 11, 2026 21:44 UTC AtaiBeckley Inc. ATAI · Entity 4289 Disposition to issuerStock Option · Derivative 1,247,932 Not disclosed Strike: $1.64 Not disclosed
Disclosure

SEC source: 0001140361-26-036377 · form4.xml · derivative · entry 7

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,247,932 shares

Expires 2034-01-05

F4 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

Read SEC document
September 11, 2026 Filed Sep 11, 2026 21:44 UTC AtaiBeckley Inc. ATAI · Entity 4289 Disposition to issuerStock Option · Derivative 17,930 Not disclosed Strike: $1.88 Not disclosed
Disclosure

SEC source: 0001140361-26-036377 · form4.xml · derivative · entry 6

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,930 shares

Expires 2033-05-23

F4 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

Read SEC document
September 11, 2026 Filed Sep 11, 2026 21:44 UTC AtaiBeckley Inc. ATAI · Entity 4289 Disposition to issuerStock Option · Derivative 64,000 Not disclosed Strike: $3.84 Not disclosed
Disclosure

SEC source: 0001140361-26-036377 · form4.xml · derivative · entry 5

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 64,000 shares

Expires 2032-05-25

F4 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

Read SEC document
September 11, 2026 Filed Sep 11, 2026 21:44 UTC AtaiBeckley Inc. ATAI · Entity 4289 Disposition to issuerStock Option · Derivative 624,000 Not disclosed Strike: $5.68 Not disclosed
Disclosure

SEC source: 0001140361-26-036377 · form4.xml · derivative · entry 4

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 624,000 shares

Expires 2030-08-20

F4 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

Read SEC document
September 11, 2026 Filed Sep 11, 2026 21:44 UTC AtaiBeckley Inc. ATAI · Entity 4289 Disposition to issuerCommon Stock 1,799,302 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-26-036377 · form4.xml · nonDerivative · entry 3

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By ApeironPresightCapital FundII, L.P.

Disclosed balance after: 0

F1 · price: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.

F2 · price: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding.

Read SEC document
September 11, 2026 Filed Sep 11, 2026 21:44 UTC AtaiBeckley Inc. ATAI · Entity 4289 Disposition to issuerCommon Stock 53,398,214 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-26-036377 · form4.xml · nonDerivative · entry 2

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By ApeironInvestmentGroup Ltd.

Disclosed balance after: 0

F1 · price: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.

F2 · price: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding.

F3 · balance_after: The Reporting Person's prior Form 4 inadvertently reported an incorrect beneficial ownership total, which has been corrected in this Form 4.

Read SEC document
September 11, 2026 Filed Sep 11, 2026 21:44 UTC AtaiBeckley Inc. ATAI · Entity 4289 Disposition to issuerCommon Stock 559,232 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-26-036377 · form4.xml · nonDerivative · entry 1

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.

F2 · price: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding.

Read SEC document
September 09, 2026 Filed Sep 9, 2026 23:08 UTC Enhanced Group Inc. ENHA · Entity 6262 PurchaseClass A Common Stock 99,342 $1.60 $159,374.37
Disclosure

SEC source: 0001193125-26-386771 · ownership.xml · nonDerivative · entry 3

Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner

Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 37,263,771

F1 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Ltd. ("Apeiron"), as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
September 08, 2026 Filed Sep 9, 2026 23:08 UTC Enhanced Group Inc. ENHA · Entity 6262 PurchaseClass A Common Stock 59,337 $1.57 $93,076.02
Disclosure

SEC source: 0001193125-26-386771 · ownership.xml · nonDerivative · entry 2

Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner

Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 37,164,429

F1 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Ltd. ("Apeiron"), as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
September 04, 2026 Filed Sep 9, 2026 23:08 UTC Enhanced Group Inc. ENHA · Entity 6262 PurchaseClass A Common Stock 21,034 $1.61 $33,898.39
Disclosure

SEC source: 0001193125-26-386771 · ownership.xml · nonDerivative · entry 1

Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner

Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 37,105,092

F1 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Ltd. ("Apeiron"), as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
September 03, 2026 Filed Sep 4, 2026 20:30 UTC Enhanced Group Inc. ENHA · Entity 6262 PurchaseClass A Common Stock 25,414 $1.58 $40,151.58
Disclosure

SEC source: 0001193125-26-383717 · ownership.xml · nonDerivative · entry 2

Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner

Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 37,084,058

F1 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Ltd. ("Apeiron"), as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
September 02, 2026 Filed Sep 4, 2026 20:30 UTC Enhanced Group Inc. ENHA · Entity 6262 PurchaseClass A Common Stock 107,693 $1.58 $169,627.24
Disclosure

SEC source: 0001193125-26-383717 · ownership.xml · nonDerivative · entry 1

Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner

Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 37,058,644

F1 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Ltd. ("Apeiron"), as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
August 19, 2026 Filed Aug 20, 2026 11:30 UTC Enhanced Group Inc. ENHA · Entity 6262 PurchaseClass A Common Stock 55,000 $1.64 $90,381.50
Disclosure

SEC source: 0001193125-26-357979 · ownership.xml · nonDerivative · entry 4

Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner

Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 36,950,951

F3 · ownership.nature: The securities reported herein are held of record by Apeiron, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
August 19, 2026 Filed Aug 20, 2026 11:30 UTC Enhanced Group Inc. ENHA · Entity 6262 PurchaseClass A Common Stock 1,619,316 $1.66 $2,688,064.56
Disclosure

SEC source: 0001193125-26-357979 · ownership.xml · nonDerivative · entry 3

Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner

Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 36,895,951

F3 · ownership.nature: The securities reported herein are held of record by Apeiron, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
August 18, 2026 Filed Aug 20, 2026 11:30 UTC Enhanced Group Inc. ENHA · Entity 6262 PurchaseClass A Common Stock 93,000 $1.70 $158,211.60
Disclosure

SEC source: 0001193125-26-357979 · ownership.xml · nonDerivative · entry 2

Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner

Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 35,276,635

F3 · ownership.nature: The securities reported herein are held of record by Apeiron, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
August 17, 2026 Filed Aug 18, 2026 12:55 UTC Enhanced Group Inc. ENHA · Entity 6262 PurchaseClass A Common Stock 200,000 $1.65 $330,420.00
Disclosure

SEC source: 0001193125-26-354788 · ownership.xml · nonDerivative · entry 1

Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner

Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 33,062,812

F1 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Limited, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron Investment Group Ltd., which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
August 14, 2026 Filed Aug 17, 2026 10:10 UTC Enhanced Group Inc. ENHA · Entity 6262 PurchaseClass A Common Stock 150,000 $1.97 $295,620.00
Disclosure

SEC source: 0001193125-26-353161 · ownership.xml · nonDerivative · entry 1

Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner

Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 32,862,812

F1 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Limited, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron Investment Group Ltd., which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
August 14, 2026 Filed Aug 20, 2026 11:30 UTC Enhanced Group Inc. ENHA · Entity 6262 GrantWarrants · Derivative 2,120,823 Not disclosed Strike: $3.89 Not disclosed
Disclosure

SEC source: 0001193125-26-357979 · ownership.xml · derivative · entry 5

Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner

Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 5,141,388

Underlying: Class A Common Stock · 2,120,823 shares

Expires not disclosed

F1 · price: Represents securities received pursuant to a securities purchase agreement between the Issuer and Apeiron Investment Group Ltd. ("Apeiron"), pursuant to which the Issuer agreed to issue and sell in tranches to Apeiron in a private placement (the "Private Placement") (A) 5,141,388 shares of Class A Common Stock and (B) warrants to purchase 5,141,388 shares of Class A Common Stock (the "Warrants"). The Class A Common Stock and Warrants will be issued separately. The combined purchase price per share of Class A Common Stock and accompanying Warrant is $3.89. On August 14, 2026, the second tranche of the Private Placement closed.

F4 · derivative.exercise_date: The Warrants are currently exercisable and have a five-year term, which may be accelerated if the Class A Common Stock trades at or above $20 for at least twenty consecutive trading days.

F4 · derivative.expiration_date: The Warrants are currently exercisable and have a five-year term, which may be accelerated if the Class A Common Stock trades at or above $20 for at least twenty consecutive trading days.

F3 · ownership.nature: The securities reported herein are held of record by Apeiron, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
August 14, 2026 Filed Aug 20, 2026 11:30 UTC Enhanced Group Inc. ENHA · Entity 6262 GrantClass A Common Stock 2,120,823 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-357979 · ownership.xml · nonDerivative · entry 1

Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner

Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 35,183,635

F1 · kind: Represents securities received pursuant to a securities purchase agreement between the Issuer and Apeiron Investment Group Ltd. ("Apeiron"), pursuant to which the Issuer agreed to issue and sell in tranches to Apeiron in a private placement (the "Private Placement") (A) 5,141,388 shares of Class A Common Stock and (B) warrants to purchase 5,141,388 shares of Class A Common Stock (the "Warrants"). The Class A Common Stock and Warrants will be issued separately. The combined purchase price per share of Class A Common Stock and accompanying Warrant is $3.89. On August 14, 2026, the second tranche of the Private Placement closed.

F1 · price: Represents securities received pursuant to a securities purchase agreement between the Issuer and Apeiron Investment Group Ltd. ("Apeiron"), pursuant to which the Issuer agreed to issue and sell in tranches to Apeiron in a private placement (the "Private Placement") (A) 5,141,388 shares of Class A Common Stock and (B) warrants to purchase 5,141,388 shares of Class A Common Stock (the "Warrants"). The Class A Common Stock and Warrants will be issued separately. The combined purchase price per share of Class A Common Stock and accompanying Warrant is $3.89. On August 14, 2026, the second tranche of the Private Placement closed.

F2 · balance_after: The total in Column 5 of Table I represents the amount of Class A Common Stock held by the Reporting Persons as of the date of this filing.

F3 · ownership.nature: The securities reported herein are held of record by Apeiron, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
July 22, 2026 Filed Jul 24, 2026 22:30 UTC Enhanced Group Inc. ENHA · Entity 6262 GrantWarrants · Derivative 3,020,565 Not disclosed Strike: $3.89 Not disclosed
Disclosure

SEC source: 0001193125-26-316451 · ownership.xml · derivative · entry 2

Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner

Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 3,020,565

Underlying: Class A Common Stock · 3,020,565 shares

Expires not disclosed

F1 · price: Represents securities received pursuant to a securities purchase agreement between the Issuer and Apeiron Investment Group Ltd. ("Apeiron"), pursuant to which the Issuer agreed to issue and sell in tranches to Apeiron in a private placement (the "Private Placement") (A) 5,141,388 shares of Class A Common Stock and (B) warrants to purchase 5,141,388 shares of Class A Common Stock (the "Warrants"). The Class A Common Stock and Warrants will be issued separately. The combined purchase price per share of Class A Common Stock and accompanying Warrant is $3.89. On July 22, 2026, the first tranche of the Private Placement closed.

F3 · derivative.exercise_date: The Warrants are currently exercisable and have a five-year term, which may be accelerated if the Class A Common Stock trades at or above $20 for at least twenty consecutive trading days.

F3 · derivative.expiration_date: The Warrants are currently exercisable and have a five-year term, which may be accelerated if the Class A Common Stock trades at or above $20 for at least twenty consecutive trading days.

F2 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Limited, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron Investment Group Ltd., which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
July 22, 2026 Filed Jul 24, 2026 22:30 UTC Enhanced Group Inc. ENHA · Entity 6262 GrantClass A Common Stock 3,020,565 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-316451 · ownership.xml · nonDerivative · entry 1

Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner

Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 32,712,812

F1 · kind: Represents securities received pursuant to a securities purchase agreement between the Issuer and Apeiron Investment Group Ltd. ("Apeiron"), pursuant to which the Issuer agreed to issue and sell in tranches to Apeiron in a private placement (the "Private Placement") (A) 5,141,388 shares of Class A Common Stock and (B) warrants to purchase 5,141,388 shares of Class A Common Stock (the "Warrants"). The Class A Common Stock and Warrants will be issued separately. The combined purchase price per share of Class A Common Stock and accompanying Warrant is $3.89. On July 22, 2026, the first tranche of the Private Placement closed.

F1 · price: Represents securities received pursuant to a securities purchase agreement between the Issuer and Apeiron Investment Group Ltd. ("Apeiron"), pursuant to which the Issuer agreed to issue and sell in tranches to Apeiron in a private placement (the "Private Placement") (A) 5,141,388 shares of Class A Common Stock and (B) warrants to purchase 5,141,388 shares of Class A Common Stock (the "Warrants"). The Class A Common Stock and Warrants will be issued separately. The combined purchase price per share of Class A Common Stock and accompanying Warrant is $3.89. On July 22, 2026, the first tranche of the Private Placement closed.

F2 · ownership.nature: The securities reported herein are held of record by Apeiron Investment Group Limited, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron Investment Group Ltd., which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
May 07, 2026 Filed May 11, 2026 22:51 UTC Enhanced Group Inc. ENHA · Entity 6262 GrantWarrants · Derivative 212,499 Not disclosed Strike: $10.00 Not disclosed
Disclosure

SEC source: 0001193125-26-217397 · ownership.xml · derivative · entry 3

Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner

Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 212,499

Underlying: Class A Common Stock · 212,499 shares

Expires not disclosed

F1 · price: Represents securities received as part of the Issuer's business combination, in connection with that certain Agreement and Plan of Merger, dated as of November 26, 2025 (the "Merger Agreement"), by and between the Issuer (formerly A Paradise Acquisition Corp.), A Paradise Merger Sub I, Inc. and Enhanced Ltd.

F3 · derivative.exercise_date: The warrants are currently exercisable and have a two-year term, which may be accelerated if the Class A Common Stock trades at or above $15 for at least twenty of thirty consecutive trading days.

F3 · derivative.expiration_date: The warrants are currently exercisable and have a two-year term, which may be accelerated if the Class A Common Stock trades at or above $15 for at least twenty of thirty consecutive trading days.

F2 · ownership.nature: The securities are held directly by Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron Investment Group Ltd., which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities held directly by Enhanced Holdings LP. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
May 07, 2026 Filed May 11, 2026 22:51 UTC Enhanced Group Inc. ENHA · Entity 6262 GrantClass B Common Stock 258,837,933 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-217397 · ownership.xml · nonDerivative · entry 2

Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner

Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 258,837,933

F1 · kind: Represents securities received as part of the Issuer's business combination, in connection with that certain Agreement and Plan of Merger, dated as of November 26, 2025 (the "Merger Agreement"), by and between the Issuer (formerly A Paradise Acquisition Corp.), A Paradise Merger Sub I, Inc. and Enhanced Ltd.

F1 · price: Represents securities received as part of the Issuer's business combination, in connection with that certain Agreement and Plan of Merger, dated as of November 26, 2025 (the "Merger Agreement"), by and between the Issuer (formerly A Paradise Acquisition Corp.), A Paradise Merger Sub I, Inc. and Enhanced Ltd.

F2 · ownership.nature: The securities are held directly by Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron Investment Group Ltd., which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities held directly by Enhanced Holdings LP. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
May 07, 2026 Filed May 11, 2026 22:51 UTC Enhanced Group Inc. ENHA · Entity 6262 GrantClass A Common Stock 29,692,247 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-217397 · ownership.xml · nonDerivative · entry 1

Apeiron Investment Group Ltd. · CIK 0001845711 · Director · 10% owner

Enhanced Holdings LP · CIK 0002132854 · Director · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 29,692,247

F1 · kind: Represents securities received as part of the Issuer's business combination, in connection with that certain Agreement and Plan of Merger, dated as of November 26, 2025 (the "Merger Agreement"), by and between the Issuer (formerly A Paradise Acquisition Corp.), A Paradise Merger Sub I, Inc. and Enhanced Ltd.

F1 · price: Represents securities received as part of the Issuer's business combination, in connection with that certain Agreement and Plan of Merger, dated as of November 26, 2025 (the "Merger Agreement"), by and between the Issuer (formerly A Paradise Acquisition Corp.), A Paradise Merger Sub I, Inc. and Enhanced Ltd.

F2 · ownership.nature: The securities are held directly by Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron Investment Group Ltd., which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities held directly by Enhanced Holdings LP. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Read SEC document
April 08, 2026 Filed Apr 10, 2026 22:00 UTC AtaiBeckley Inc. ATAI · Entity 4289 Exercise / conversionStock Option · Derivative 103,000 $0.00 Strike: $1.34 $0.00
Disclosure

SEC source: 0001140361-26-014300 · form4.xml · derivative · entry 8

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 103,000 shares

Expires 2034-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
April 08, 2026 Filed Apr 10, 2026 22:00 UTC AtaiBeckley Inc. ATAI · Entity 4289 Exercise / conversionStock Option · Derivative 410,162 $0.00 Strike: $1.64 $0.00
Disclosure

SEC source: 0001140361-26-014300 · form4.xml · derivative · entry 7

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 231,838

Underlying: Common Stock · 410,162 shares

Expires 2034-01-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option vested with respect to 25% of the shares on January 5, 2025, and will vest with respect to the remaining shares in 36 monthly installments thereafter.

Read SEC document
April 08, 2026 Filed Apr 10, 2026 22:00 UTC AtaiBeckley Inc. ATAI · Entity 4289 Exercise / conversionStock Option · Derivative 46,070 $0.00 Strike: $1.88 $0.00
Disclosure

SEC source: 0001140361-26-014300 · form4.xml · derivative · entry 6

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,930

Underlying: Common Stock · 46,070 shares

Expires 2033-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
April 08, 2026 Filed Apr 10, 2026 22:00 UTC AtaiBeckley Inc. ATAI · Entity 4289 Exercise / conversionCommon Stock 103,000 $1.34 $138,020.00
Disclosure

SEC source: 0001140361-26-014300 · form4.xml · nonDerivative · entry 3

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 559,232

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares acquired upon exercise of options and held by the Reporting Person.

Read SEC document
April 08, 2026 Filed Apr 10, 2026 22:00 UTC AtaiBeckley Inc. ATAI · Entity 4289 Exercise / conversionCommon Stock 410,162 $1.64 $672,665.68
Disclosure

SEC source: 0001140361-26-014300 · form4.xml · nonDerivative · entry 2

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 456,232

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares acquired upon exercise of options and held by the Reporting Person.

Read SEC document
April 08, 2026 Filed Apr 10, 2026 22:00 UTC AtaiBeckley Inc. ATAI · Entity 4289 Exercise / conversionCommon Stock 46,070 $1.88 $86,611.60
Disclosure

SEC source: 0001140361-26-014300 · form4.xml · nonDerivative · entry 1

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,070

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares acquired upon exercise of options and held by the Reporting Person.

Read SEC document
September 30, 2025 Filed Oct 2, 2025 16:18 UTC Atai Beckley N.V. ATAI · Entity 72536 ConversionConvertible Notes · Derivative 147,950 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-25-228361 · ownership.xml · derivative · entry 3

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Apeiron Investment Group Ltd.

Disclosed balance after: 0

Underlying: Common Shares · 2,367,200 shares

Expires 2025-09-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The conversion price for the Convertible Notes is EUR 17.00 per note.

F2 · price: The Convertible Notes were acquired in exchange for convertible notes issued by ATAI Life Sciences AG with substantially similar terms and economics.

Read SEC document
September 30, 2025 Filed Oct 2, 2025 16:18 UTC Atai Beckley N.V. ATAI · Entity 72536 ConversionCommon Shares 2,367,200 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-25-228361 · ownership.xml · nonDerivative · entry 1

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Apeiron Investment Group Ltd.

Disclosed balance after: 53,412,414

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The conversion price for the Convertible Notes is EUR 17.00 per note.

Read SEC document
August 14, 2025 Filed Aug 18, 2025 18:00 UTC Atai Beckley N.V. ATAI · Entity 72536 PurchaseCommon Shares 8,675,799 $2.19 $18,999,999.81
Disclosure

SEC source: 0000950170-25-109858 · ownership.xml · nonDerivative · entry 1

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Apeiron Investment Group Ltd.

Disclosed balance after: 51,045,214

Read SEC document
March 24, 2025 Filed Mar 24, 2025 17:00 UTC Atai Beckley N.V. ATAI · Entity 72536 PurchaseCommon Shares 1,800,000 $1.40 $2,520,000.00
Disclosure

SEC source: 0000950170-25-043942 · ownership.xml · nonDerivative · entry 1

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Apeiron Investment Group Ltd.

Disclosed balance after: 42,369,415

Read SEC document
February 14, 2025 Filed Feb 19, 2025 18:00 UTC Atai Beckley N.V. ATAI · Entity 72536 PurchaseCommon Shares 10,835,718 $2.10 $22,755,007.80
Disclosure

SEC source: 0000950170-25-023436 · ownership.xml · nonDerivative · entry 1

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Angermayer Christian · CIK 0001845872 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Apeiron Investment Group Ltd.

Disclosed balance after: 40,555,215

Read SEC document
October 04, 2024 Filed Oct 7, 2024 18:22 UTC BIONOMICS LTD/ADR BNOX · Entity 86952 SaleOrdinary Shares 557 $0.28 $155.96
Disclosure

SEC source: 0000950170-24-113344 · ownership.xml · nonDerivative · entry 3

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · 10% owner

Angermayer Christian · CIK 0001845872 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P.

Disclosed balance after: 93,369,060

F1 · security: Includes Ordinary Shares represented by American Depositary Shares.

F2 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.

Read SEC document
October 03, 2024 Filed Oct 7, 2024 18:22 UTC BIONOMICS LTD/ADR BNOX · Entity 86952 SaleOrdinary Shares 180,707 $0.29 $52,405.03
Disclosure

SEC source: 0000950170-24-113344 · ownership.xml · nonDerivative · entry 2

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · 10% owner

Angermayer Christian · CIK 0001845872 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P.

Disclosed balance after: 93,469,320

F1 · security: Includes Ordinary Shares represented by American Depositary Shares.

F2 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.

Read SEC document
October 02, 2024 Filed Oct 7, 2024 18:22 UTC BIONOMICS LTD/ADR BNOX · Entity 86952 SaleOrdinary Shares 90,806 $0.33 $29,965.98
Disclosure

SEC source: 0000950170-24-113344 · ownership.xml · nonDerivative · entry 1

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · 10% owner

Angermayer Christian · CIK 0001845872 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P.

Disclosed balance after: 125,996,580

F1 · security: Includes Ordinary Shares represented by American Depositary Shares.

F2 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.

Read SEC document
April 15, 2024 Filed Apr 17, 2024 16:15 UTC Atai Beckley N.V. ATAI · Entity 72536 OtherConvertible Notes · Derivative 147,950 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-045120 · ownership.xml · derivative · entry 2

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Angermayer Christian · CIK 0001845872 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Apeiron Investment Group Ltd.

Disclosed balance after: 147,950

Underlying: Common Shares · 2,367,200 shares

Expires 2025-09-30

F1 · derivative.exercise_price: The conversion price for the Convertible Notes is EUR 17.00 per note.

F2 · kind: Represents an exchange of Convertible Notes issued by ATAI Life Sciences AG for Convertible Notes issued by the Issuer with substantially similar terms and economics.

F3 · shares: Each Convertible Note bears a notional principal amount of EUR 1.00.

F2 · price: Represents an exchange of Convertible Notes issued by ATAI Life Sciences AG for Convertible Notes issued by the Issuer with substantially similar terms and economics.

F3 · balance_after: Each Convertible Note bears a notional principal amount of EUR 1.00.

F4 · ownership.nature: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.

Read SEC document
April 15, 2024 Filed Apr 17, 2024 16:15 UTC Atai Beckley N.V. ATAI · Entity 72536 OtherConvertible Notes · Derivative 147,950 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-045120 · ownership.xml · derivative · entry 1

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Angermayer Christian · CIK 0001845872 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Apeiron Investment Group Ltd.

Disclosed balance after: 0

Underlying: Common Shares · 2,367,200 shares

Expires not disclosed

F1 · derivative.exercise_price: The conversion price for the Convertible Notes is EUR 17.00 per note.

F2 · kind: Represents an exchange of Convertible Notes issued by ATAI Life Sciences AG for Convertible Notes issued by the Issuer with substantially similar terms and economics.

F3 · shares: Each Convertible Note bears a notional principal amount of EUR 1.00.

F2 · price: Represents an exchange of Convertible Notes issued by ATAI Life Sciences AG for Convertible Notes issued by the Issuer with substantially similar terms and economics.

F2 · derivative.exercise_date: Represents an exchange of Convertible Notes issued by ATAI Life Sciences AG for Convertible Notes issued by the Issuer with substantially similar terms and economics.

F2 · derivative.expiration_date: Represents an exchange of Convertible Notes issued by ATAI Life Sciences AG for Convertible Notes issued by the Issuer with substantially similar terms and economics.

F4 · ownership.nature: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.

Read SEC document
February 06, 2024 Filed Mar 6, 2024 14:15 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 ConversionSeries B Preferred Stock · Derivative 416,665 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-026885 · ownership.xml · derivative · entry 6

Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks

Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks

Angermayer Christian · CIK 0001845872 · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 196,299 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis.

F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.

F5 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis.

F5 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis.

F3 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.

Read SEC document
February 06, 2024 Filed Mar 6, 2024 14:15 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 ConversionSeries A Preferred Stock · Derivative 1,063,918 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-026885 · ownership.xml · derivative · entry 5

Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks

Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks

Angermayer Christian · CIK 0001845872 · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 478,359 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.

F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.

F1 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.

F1 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.

F3 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.

Read SEC document
February 06, 2024 Filed Mar 6, 2024 14:15 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 ConversionSeries A Preferred Stock · Derivative 406,072 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-026885 · ownership.xml · derivative · entry 4

Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks

Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks

Angermayer Christian · CIK 0001845872 · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 182,577 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.

F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.

F1 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.

F1 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.

F2 · ownership.direct: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.

Read SEC document
February 06, 2024 Filed Mar 6, 2024 14:15 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 ConversionWarrants to Purchase Series A Preferred Stock · Derivative 444,561 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-026885 · ownership.xml · derivative · entry 3

Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks

Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks

Angermayer Christian · CIK 0001845872 · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 69,304 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis.

F4 · price: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis.

F4 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis.

F4 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis.

F2 · ownership.direct: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.

Read SEC document
February 06, 2024 Filed Mar 6, 2024 14:15 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 ConversionCommon Stock 674,658 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-026885 · ownership.xml · nonDerivative · entry 2

Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks

Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks

Angermayer Christian · CIK 0001845872 · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Apeiron Presight Capital Fund II, L.P.(

Disclosed balance after: 674,658

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.

F3 · ownership.nature: The reportable securities are held by Apeiron Presight Capital Fund II, L.P. ("Apeiron Presight"). Apeiron Investment Group Ltd. ("Apeiron") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. ("Presight Management"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities.

Read SEC document
February 06, 2024 Filed Mar 6, 2024 14:15 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 ConversionCommon Stock 251,881 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-026885 · ownership.xml · nonDerivative · entry 1

Apeiron Investment Group Ltd. · CIK 0001845711 · See Remarks

Apeiron Presight Capital Fund II, L.P. · CIK 0001840676 · See Remarks

Angermayer Christian · CIK 0001845872 · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 251,881

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis.

F2 · ownership.direct: The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.